Sagimet Biosciences Inc (SGMT)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$9.58-3.72%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Sagimet Biosciences Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	166,667
EPS	—	-0.281
Annual ending 2026-12-31
Revenue	—	111,111
EPS	—	-1.127
Annual ending 2027-12-31
Revenue	—	8.13M
EPS	—	-1.344

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Limit EPS losses to consensus estimates	A primary condition in Sagimet Biosciences Inc's published investment case. The stated target is EPS no worse than -$1.31 in FY27.	Improving	EPS falls below -$1.31 in FY27	Diluted EPS: $-0.26 per share FY2026-Q2; GAAP. Published target: EPS no worse than -$1.31 in FY27. Target period is not explicitly aligned with this observation. Source published Aug 11, 2026-0.26 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: d7c5b552-a798-4012-826e-12b0388ba4ea. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Advance denifanstat into and through Phase 3 trial	Sagimet is advancing its lead drug denifanstat to Phase 3 trials.	Intact	Phase 3 trial initiation delayed beyond 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Generate initial revenue from drug sales or partnerships	A supporting condition in Sagimet Biosciences Inc's published investment case. The stated target is Achieve revenue of at least $7.8 million in FY27.	Intact	Revenue fails to reach $7.8 million in FY27	Revenue: $0 FY2026-Q2; GAAP. Published target: Achieve revenue of at least $7.8 million in FY27. Target period is not explicitly aligned with this observation. Source published Aug 11, 20260 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-1.34

$-1.25 → $-1.34 · observed estimates

FY2027 revenue$0.01B

$0.01B → $0.01B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-1.25	$7,526,500	7 / 6
2026-07-25	$-1.25	$7,526,500	7 / 6
2026-07-26	$-1.25	$7,526,500	7 / 6
2026-07-27	$-1.25	$7,526,500	7 / 6
2026-07-28	$-1.25	$7,526,500	7 / 6
2026-07-29	$-1.25	$7,526,500	7 / 6
2026-07-30	$-1.25	$7,526,500	7 / 6
2026-07-31	$-1.31	$7,807,220	9 / 9
2026-08-01	$-1.25	$7,526,500	7 / 6
2026-08-02	$-1.31	$7,807,220	9 / 9
2026-08-03	$-1.25	$7,526,500	7 / 6
2026-08-04	$-1.31	$7,807,220	9 / 9
2026-08-05	$-1.25	$7,526,500	7 / 6
2026-08-06	$-1.31	$7,807,220	9 / 9
2026-08-08	$-1.31	$7,807,220	9 / 9
2026-08-09	$-1.25	$7,526,500	7 / 6
2026-08-10	$-1.31	$7,807,220	9 / 9
2026-08-12	$-1.25	$7,526,500	7 / 6
2026-08-13	$-1.25	$7,526,500	7 / 6
2026-08-14	$-1.25	$7,526,500	7 / 6
2026-08-15	$-1.25	$7,526,500	7 / 6
2026-08-16	$-1.25	$7,526,500	7 / 6
2026-08-17	$-1.25	$7,526,500	7 / 6
2026-08-18	$-1.25	$7,526,500	7 / 6
2026-08-19	$-1.25	$7,526,500	7 / 6
2026-08-20	$-1.38	$7,526,500	7 / 6
2026-08-21	$-1.36	$7,526,500	7 / 6
2026-08-22	$-1.36	$7,526,500	7 / 6
2026-08-23	$-1.36	$7,526,500	7 / 6
2026-08-24	$-1.36	$7,526,500	7 / 6
2026-08-25	$-1.36	$7,526,500	7 / 6
2026-08-26	$-1.39	$7,526,500	7 / 6
2026-08-27	$-1.39	$7,526,500	7 / 6
2026-08-28	$-1.39	$7,526,500	7 / 6
2026-08-29	$-1.39	$7,526,500	7 / 6
2026-08-30	$-1.39	$7,526,500	7 / 6
2026-08-31	$-1.39	$7,526,500	7 / 6
2026-09-01	$-1.39	$7,526,500	7 / 6
2026-09-02	$-1.39	$7,526,500	7 / 6
2026-09-03	$-1.39	$7,526,500	7 / 6
2026-09-04	$-1.39	$7,526,500	7 / 6
2026-09-05	$-1.39	$7,526,500	7 / 6
2026-09-06	$-1.39	$7,526,500	7 / 6
2026-09-07	$-1.39	$7,526,500	7 / 6
2026-09-08	$-1.39	$7,526,500	7 / 6
2026-09-09	$-1.39	$7,526,500	7 / 6
2026-09-10	$-1.41	$7,328,618	7 / 6
2026-09-11	$-1.41	$7,328,618	7 / 6
2026-09-12	$-1.41	$7,328,618	8 / 7
2026-09-13	$-1.41	$7,328,618	8 / 7
2026-09-14	$-1.41	$7,328,618	8 / 7
2026-09-15	$-1.41	$7,328,618	8 / 7
2026-09-16	$-1.41	$7,328,618	8 / 7
2026-09-17	$-1.41	$7,328,618	8 / 7
2026-09-18	$-1.41	$7,328,618	8 / 7
2026-09-19	$-1.41	$7,328,618	8 / 7
2026-09-20	$-1.41	$7,328,618	8 / 7
2026-09-21	$-1.41	$7,328,618	8 / 7
2026-09-22	$-1.41	$7,328,618	8 / 7
2026-09-23	$-1.41	$7,328,618	8 / 7
2026-09-24	$-1.41	$7,328,618	8 / 7
2026-09-25	$-1.42	$7,175,233	8 / 7
2026-09-26	$-1.42	$7,175,233	8 / 7
2026-09-27	$-1.42	$7,175,233	8 / 7
2026-09-28	$-1.42	$7,175,233	8 / 7
2026-09-29	$-1.42	$7,175,233	8 / 7
2026-09-30	$-1.42	$7,175,233	8 / 7
2026-10-01	$-1.42	$7,175,233	8 / 7
2026-10-02	$-1.38	$8,132,332	8 / 7
2026-10-03	$-1.36	$8,132,332	8 / 7
2026-10-04	$-1.36	$8,132,332	8 / 7
2026-10-05	$-1.36	$8,132,332	8 / 7
2026-10-06	$-1.34	$8,132,332	8 / 7
2026-10-07	$-1.34	$8,132,332	8 / 7
2026-10-08	$-1.34	$8,132,332	8 / 7
2026-10-09	$-1.34	$8,132,332	8 / 7
2026-10-10	$-1.34	$8,132,332	8 / 7
2026-10-11	$-1.34	$8,132,332	8 / 7
2026-10-12	$-1.34	$8,132,332	8 / 7
2026-10-13	$-1.34	$8,132,332	8 / 7
2026-10-14	$-1.34	$8,132,332	8 / 7
2026-10-15	$-1.34	$8,132,332	8 / 7
2026-10-16	$-1.34	$8,132,332	8 / 7
2026-10-17	$-1.34	$8,132,332	8 / 7
2026-10-18	$-1.34	$8,132,332	8 / 7
2026-10-19	$-1.34	$8,132,332	8 / 7
2026-10-20	$-1.34	$8,132,332	8 / 7
2026-10-21	$-1.34	$8,132,332	8 / 7
2026-10-22	$-1.34	$8,132,332	8 / 7
2026-10-23	$-1.34	$8,132,332	8 / 7
2026-10-24	$-1.34	$8,132,332	8 / 7

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	9	1	0
2026-06-01	9	1	0
2026-07-01	9	1	0
2026-08-01	9	1	0
2026-09-01	11	1	1
2026-10-01	11	0	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 11 Buy / Strong Buy · 0 Hold · 1 Sell / Strong Sell

0 upgrades0 downgrades4 maintains

Recent actions · Sep 25–Oct 24 · 4 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

GuggenheimOct 2

$26.00New observation · no comparable prior

H.C. WainwrightSep 28

$29.00New observation · no comparable prior

$0$15.95$31.90

0 raises · 0 cuts · 0 unchanged · 2 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Limit EPS losses to consensus estimatesDiluted EPS: $-0.26 per share
Advance denifanstat into and through Phase 3 trialDirect metric needs a verified mapping
Generate initial revenue from drug sales or partnershipsRevenue: $0

Next proof point

Nov 12, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.3%Typical daily move · historical

Downside history

-50.2%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Sagimet Biosciences Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative clinical-stage biotech, not an established earnings compounder, because it is loss-making and its thesis rests on drug development. The long-term thesis is in a watch state: denifanstat has entered its planned Phase 3 acne trial, while TVB-3567’s Phase 2 start is still prospective.

What's priced into Sagimet Biosciences Inc

The evidence does not provide a valuation comparison or a clear account of what the market already assumes, so whether SGMT is cheap, fair, or expensive versus peers cannot be assessed here. No fragility gates fired, but the available evidence is too limited to define an expectations gap.

What the fundamentals likely do

Near term, the company is likely to remain loss-making as it advances clinical trials; reported cash and a September financing support funding through mid-2029. Execution has been mixed: the first patient was dosed in the denifanstat Phase 3 trial, while the TVB-3567 Phase 2 trial is expected to start before the end of 2026. Near-term risk remains elevated, and the evidence flags a meaningful possibility of a miss at the next report.

What Sagimet Biosciences Inc hinges on

The multi-year thesis hinges on clinical progress, especially whether TVB-3567 enters Phase 2 as expected and whether denifanstat advances through Phase 3. A guidance cut or further weakness in jobs data could weigh on the near-term outlook, while continued strength among healthcare sector leaders could provide a more supportive backdrop.